A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

ישראלמגייס משתתפיםPHASE2, PHASE3

מצבים רפואיים

DLBCL · Diffuse Large B-Cell Lymphoma

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Emek Medical Center-Hematology Unit ( Site 1102), Afula, Israel

  • Carmel Hospital ( Site 1103), Haifa, Israel

  • Hadassah Medical Center ( Site 1100), Jerusalem, Israel

  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175), Glendale, Arizona, United States

    Study coordinator · 602-978-6255
  • Beverly Hills Cancer Center ( Site 0184), Beverly Hills, California, United States

    Study coordinator · 310-432-8900
  • Bass Medical Group ( Site 0166), Walnut Creek, California, United States

    Study coordinator · 925-433-8786
  • Innovative Clinical Research Institute ( Site 0122), Whittier, California, United States

  • Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida, United States

    Study coordinator · 561-955-4145
  • Clermont Oncology Center ( Site 0174), Clermont, Florida, United States

    Study coordinator · 352-242-1366
  • BRP-Hialeah Hospital ( Site 0182), Hialeah, Florida, United States

    Study coordinator · 833-489-4968
  • Illinois Cancer Specialists ( Site 8000), Niles, Illinois, United States

    Study coordinator · 847-827-9060
  • Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky, United States

    Study coordinator · 859-301-2000
  • University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky, United States

    Study coordinator · 859-257-3379
  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky, United States

    Study coordinator · 502-629-3681
  • University of Maryland ( Site 0123), Baltimore, Maryland, United States

    Study coordinator · 410-328-7996
  • Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts, United States

    Study coordinator · 617-632-2305
  • University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts, United States

    Study coordinator · 774-455-4446
  • Corewell Health ( Site 0162), Grand Rapids, Michigan, United States

    Study coordinator · 616-486-6180
  • St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana, United States

    Study coordinator · 406-238-6290
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0188), Grand Island, Nebraska, United States

    Study coordinator · 402-334-4773
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0177), Omaha, Nebraska, United States

    Study coordinator · 402-334-4773
  • Comprehensive Cancer Centers of Nevada ( Site 0168), Las Vegas, Nevada, United States

    Study coordinator · 702-952-3400
  • Atlantic Health System ( Site 0116), Morristown, New Jersey, United States

  • Presbyterian Rust Jorgensen Cancer ( Site 9506), Rio Rancho, New Mexico, United States

    Study coordinator · 505-559-6100
  • New York Medical College ( Site 0113), Valhalla, New York, United States

    Study coordinator · 914-594-2150
  • Alliance Cancer Specialists (ACS) ( Site 8001), Horsham, Pennsylvania, United States

    Study coordinator · 215-706-4176
  • Tennessee Cancer Specialists ( Site 7000), Knoxville, Tennessee, United States

    Study coordinator · 865-862-0998
  • Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee, United States

  • Blue Ridge Cancer Care ( Site 0169), Roanoke, Virginia, United States

    Study coordinator · 540-982-0237
  • Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

    Study coordinator · +541149590200
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata, Buenos Aires, Argentina

  • Hospital Aleman ( Site 2200), Buenos Aites, Buenos Aires F.D., Argentina

    Study coordinator · +541148277000
  • Hospital Privado Universitario de Córdoba ( Site 2202), Córdoba, Córdoba Province, Argentina

    Study coordinator · +543514688200
  • Instituto Alexander Fleming ( Site 2201), CABA, Argentina

    Study coordinator · +541132218900
  • Townsville University Hospital ( Site 1800), Douglas, Queensland, Australia

  • Grampians Health ( Site 1802), Ballarat, Victoria, Australia

    Study coordinator · +61353208500
  • Royal Perth Hospital-Haematology ( Site 1801), Perth, Western Australia, Australia

    Study coordinator · +61892242405
  • Hospital Erasto Gaertner ( Site 2302), Curitiba, Paraná, Brazil

    Study coordinator · +5541999846033
  • Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Rio Grande do Norte, Brazil

    Study coordinator · +55 (84) 99927-8442
  • Hospital Paulistano ( Site 2300), São Paulo, Brazil

    Study coordinator · +551131411083
  • Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario, Canada

  • Biocenter ( Site 2401), Concepción, Biobio, Chile

    Study coordinator · +56412858421
  • IC La Serena Research ( Site 2405), La Serena, Coquimbo Region, Chile

    Study coordinator · +56958646664
  • Oncocentro Valdivia ( Site 2407), Valdivia, Los Ríos Region, Chile

    Study coordinator · +56958537020
  • FALP-UIDO ( Site 2400), Santiago, Region M. de Santiago, Chile

  • Clínica Inmunocel ( Site 2404), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56224376600
  • Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. de Santiago, Chile

    Study coordinator · 56223954044
  • Bradfordhill ( Site 2403), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56229490970
  • Beijing Cancer hospital ( Site 3000), Beijing, Beijing Municipality, China

    Study coordinator · +8601088196698
  • Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing Municipality, China

  • Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing Municipality, China

  • Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong, China

    Study coordinator · +86-020-87343272
  • Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong, China

    Study coordinator · +86-020-61643888
  • The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan, China

  • Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan, China

    Study coordinator · 0371-65588007
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei, China

    Study coordinator · 027-85726685
  • The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi, China

  • Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi, China

    Study coordinator · 079188329441
  • The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin, China

    Study coordinator · 13756948057
  • Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai Municipality, China

    Study coordinator · 021 6417 5589
  • Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan, China

    Study coordinator · +8613668112022
  • West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Chengdu, Sichuan, China

    Study coordinator · +8618980601027
  • Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang, China

    Study coordinator · 0571 8812 2222
  • The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou, Zhejiang, China

    Study coordinator · 0571-87236114
  • Hospital Pablo Tobon Uribe ( Site 0804), Medellín, Antioquia, Colombia

    Study coordinator · 6044459753
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogotá, Bogota D.C., Colombia

    Study coordinator · 3044921963
  • Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Montería, Departamento de Córdoba, Colombia

  • Oncologos del Occidente ( Site 0800), Pereira, Risaralda Department, Colombia

    Study coordinator · +57 3187715522
  • Fundacion Valle del Lili ( Site 0802), Cali, Valle del Cauca Department, Colombia

    Study coordinator · +576023319090
  • Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, Provincia de San José, Costa Rica

    Study coordinator · +506 8497 8912
  • CIMCA ( Site 2501), San José, Costa Rica

    Study coordinator · +506 6041 6775
  • Aarhus Universitetshospital, Skejby ( Site 1701), Aarhus, Central Jutland, Denmark

    Study coordinator · +4578450000
  • centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone, France

  • Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, France

  • Evangelismos General Hospital of Athens ( Site 0900), Athens, Attica, Greece

    Study coordinator · 0030 2132041721
  • Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attica, Greece

    Study coordinator · 0030 2136060981
  • University Hospital of Alexandroupolis ( Site 0903), Alexandroupoli, East Macedonia and Thrace, Greece

    Study coordinator · 0030 2551353739
  • MEDI-K ( Site 2602), Guatemala City, Guatemala

    Study coordinator · +502 5366 8125
  • Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala City, Guatemala

    Study coordinator · +502 3014 7611
  • CELAN,S.A ( Site 2603), Guatemala City, Guatemala

    Study coordinator · +502 5200 2329
  • Queen Mary Hospital ( Site 3100), Hong Kong, Hong Kong

    Study coordinator · +85222553838
  • Princess Margaret Hospital ( Site 3101), Hong Kong, Hong Kong

  • Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano, Italy

    Study coordinator · 0282244080
  • IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Naples, Italy

    Study coordinator · 390815903382
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Italy

  • Hokkaido University Hospital ( Site 3202), Sapporo, Hokkaido, Japan

    Study coordinator · +81-11-716-1161
  • Tokai University Hospital ( Site 3212), Isehara, Kanagawa, Japan

    Study coordinator · +81-463-93-1121
  • Mie University Hospital ( Site 3210), Tsu, Mie-ken, Japan

    Study coordinator · +81-59-231-5246
  • Kansai Medical University Hospital ( Site 3203), Hirakata, Osaka, Japan

    Study coordinator · +81-72-804-2808
  • Tokyo Metropolitan Komagome Hospital ( Site 3200), Bunkyo, Tokyo, Japan

    Study coordinator · +81-3-3823-2101
  • The Jikei University Hospital ( Site 3208), Minato, Tokyo, Japan

    Study coordinator · +81-3-3433-1111
  • University of Yamanashi Hospital ( Site 3201), Chūō, Yamanashi, Japan

    Study coordinator · +81-55-273-1111
  • National Hospital Organization Kyushu Cancer Center ( Site 3204), Fukuoka, Japan

    Study coordinator · +81-92-541-3231
  • Fukushima Medical University Hospital ( Site 3207), Fukushima, Japan

    Study coordinator · +81-24-547-1111
  • University Hospital,Kyoto Prefectural University of Medicine ( Site 3209), Kyoto, Japan

    Study coordinator · +81-75-251-5871
  • University of Miyazaki Hospital ( Site 3211), Miyazaki, Japan

    Study coordinator · +81-985-85-1510
  • Osaka Metropolitan University Hospital ( Site 3205), Osaka, Japan

    Study coordinator · +81-6-6645-2121
  • Yamagata University Hospital ( Site 3206), Yamagata, Japan

    Study coordinator · +81-23-633-1122
  • Health Pharma Professional Research S.A. de C.V: ( Site 2700), Mexico City, Mexico City, Mexico

  • Medivest Centro de Investigación Integral ( Site 2704), Chihuahua City, Mexico

  • Centro de Infusion Superare ( Site 2701), Mexico City, Mexico

  • Aotearoa Clinical Trials ( Site 0501), Auckland, New Zealand

    Study coordinator · +64 9 277 1660
  • Clínicas AUNA Sede Chiclayo ( Site 2803), Chiclayo, Lambayeque, Peru

    Study coordinator · 51 74748333 Ext 7832
  • INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 2800), Surquillo, Muni Metro de Lima, Peru

    Study coordinator · +512016500
  • Clínica San Felipe ( Site 2805), Lima, Peru

    Study coordinator · 511 2039900 Ext 131
  • Hospital Nacional Edgardo Rebagliati Martins ( Site 2802), Lima, Peru

    Study coordinator · +51991895682
  • Hospital Nacional Dos De Mayo ( Site 2804), Lima, Peru

    Study coordinator · +51944464618
  • Pratia MCM Krakow ( Site 1303), Krakow, Lesser Poland Voivodeship, Poland

    Study coordinator · 0048602338290
  • Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305), Wałbrzych, Lower Silesian Voivodeship, Poland

    Study coordinator · +48746489966
  • Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301), Wroclaw, Lower Silesian Voivodeship, Poland

  • Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lublin Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300), Warsaw, Masovian Voivodeship, Poland

    Study coordinator · 0048225462366
  • Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomeranian Voivodeship, Poland

  • Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomeranian Voivodeship, Poland

    Study coordinator · 59 84 60 390
  • Pratia Onkologia Katowice ( Site 1306), Katowice, Silesian Voivodeship, Poland

    Study coordinator · +48600388282
  • Seoul National University Hospital-Oncology ( Site 0302), Seoul, South Korea

    Study coordinator · 82220723559
  • Samsung Medical Center ( Site 0300), Seoul, South Korea

  • Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Bangkok, Thailand

  • Chulalongkorn University ( Site 0402), Pathumwan, Bangkok, Thailand

  • Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Thailand

  • Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912), Yenimahalle, Ankara, Turkey (Türkiye)

    Study coordinator · (0312) 336 09 09
  • Ege University Medicine of Faculty ( Site 1902), Bornova, İzmir, Turkey (Türkiye)

    Study coordinator · +905325566128
  • Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Turkey (Türkiye)

    Study coordinator · +90 505 502 50 50
  • Mega Medipol-Hematology ( Site 1909), Istanbul, Turkey (Türkiye)

    Study coordinator · 444 7 044
  • Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Turkey (Türkiye)

    Study coordinator · +905425151780
  • Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Turkey (Türkiye)

  • MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkasy Oblast, Ukraine

    Study coordinator · +380472370025
  • Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

    Study coordinator · 380974668727
  • Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lviv Oblast, Ukraine

    Study coordinator · 380322352276
  • State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Ukraine

    Study coordinator · +380442571090
  • National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005), Kyiv, Ukraine

  • Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City, United Kingdom

  • The Royal Cornwall Hospital ( Site 2103), Truro, England, United Kingdom

  • University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City of, United Kingdom

מובילי המחקר
  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC